Cao Sean Wuxiong's Form 4 filing
NovaBridge Biosciences (NBP) · filed May 18, 2026
- Accession no.
- 0001193125-26-228889
- Filed
- May 18, 2026
- Trade date
- May 14, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $42.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cao Sean WuxiongCIK 0002109966 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | Ordinary Shares | SSaleDisposed | −21,399 | $1.99F3 | −$42,584.01 | 35,073 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Price expressed in terms of ADSs.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Business Development Officer and Director